[Consideration on the Research and Development of New Drugs for Rare Tumors]

Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):443-447. doi: 10.3779/j.issn.1009-3419.2022.101.26.
[Article in Chinese]

Abstract

In recent years, China's anti-tumor drugs has shown a continuous growth trend, and the activity of anti-tumor research and development in China accounts for a higher proportion in the world. However, further analysis of research and development hotspots show that the research and development of anti-tumor drugs is uneven among different tumor types. Due to the small number of the patients, it is difficult to conduct clinical trials, resulting in less drug development in the field of rare tumors. However, patients' treatment needs will also bring potential opportunities for pharmaceutical companies. The development of basic research and the discovery of new molecular tumor typing make "rare tumors" a dynamic concept. The scope of "rare tumors" may gradually expand with the precise development of treatment; or as the knowledge of tumors gradually develops from histocytology to the molecular level, It is possible that certain tumors with specific mutations can be combined into a group of non-rare "pan-tumors". Rare tumors are characterized by both rare diseases and tumors. Its drug research and development should not only meet the requirements of tumor drug research and development, but also adapt to the characteristics of rare diseases. Therefore, in the drug research and development, we can refer to the research and development principle of rare disease drugs, combine with the characteristics of tumor diseases, make full use of non-rare tumor clinical trials, make full use of scientific tools and exquisite trial design, and realize the promotion of the research and development of rare tumor drugs. This paper will summarize the thoughts in the review of new drugs in the field of rare tumors, in order to provide guidance for the industry. .

【中文题目:罕见肿瘤新药研发的思考】 【中文摘要:近年来,我国抗肿瘤药物呈现持续增长趋势,我国抗肿瘤研发的活跃程度占全球比例增高。然而,进一步分析研发热点,抗肿瘤药物在各瘤种中的研发并不均衡。对于发病率低的罕见肿瘤,由于患者少,临床试验开展难度大,研发热情普遍较低。然而,患者的治疗需求,也会为制药企业带来潜在机遇。基础研究的发展,以及新的肿瘤分子分型的发现,使“罕见肿瘤”成为一种动态的概念,“罕见肿瘤”的范围可能随着治疗的精准化发展而逐步拓宽;也可能随着对肿瘤的认识逐步由组织细胞学向分子学层面发展,使某些伴有特定突变的瘤种,共同组合成一组非罕见的“泛肿瘤”。罕见肿瘤同时具备罕见病和肿瘤的特征。其药物研发既要满足肿瘤药物研发的要求,又要适应于罕见疾病药物研发的特点,因此药物研发中可参考罕见病药物的研发思路,同时结合肿瘤疾病的特征,充分利用非罕见瘤种临床试验中的数据,充分利用科学工具、精巧的试验设计,实现对罕见肿瘤药物研发的促进。本文将对罕见肿瘤领域新药审评中的思考进行总结,以期为业界提供参考。 】 【中文关键词:罕见肿瘤;药物;研发】.

Keywords: Drug; Rare tumors; Research and development.

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • China
  • Humans
  • Lung Neoplasms* / drug therapy
  • Rare Diseases / drug therapy
  • Research

Substances

  • Antineoplastic Agents